Transplantační medicína

Comprehensive analysis of meningococcal vaccine effectiveness during Hajj pilgrimages, featuring case studies from Singapore and Saudi Arabia. Highlights significant reduction in IMD cases post-vaccination and explores the broader benefits of meningococcal conjugate vaccines, including herd immunity and reduced global transmission.

Comprehensive overview of Neisseria meningitidis, detailing bacterial characteristics, serogroups, and age-specific carriage patterns. Features evidence from European meta-analysis of 89 studies, highlighting carriage rates from infancy through adulthood and the relationship between carriage and invasive disease.

Comprehensive guide to clinical presentations of Invasive Meningococcal Disease (IMD), detailing key symptoms of meningitis, meningococcemia, and septic shock. Features diagnostic criteria including fever, headache, photophobia, petechial rash, and less common manifestations such as pneumonia and arthritis. Essential reference for healthcare providers and medical professionals.

Comprehensive analysis of Invasive Meningococcal Disease (IMD) outcomes, featuring detailed mortality rates by serogroup and age group, with focus on the 20% survivor sequelae rate. Includes comparative analysis with other vaccine-preventable diseases (VPDs) and highlights the critical 24-hour window for treatment intervention.

Impacto clínico del estudio en vida real, la disminución de la tasa anual de exacerbaciones.

Serie de 6 videos sobre el primer estudio de evidencia del mundo real sobre la efectividad de dupilumab

¿En búsqueda del control a Largo plazo plazo en la RSCcPN grave? El Dr. Alejandro Motta describe el estudio DUPIREAL, evidencia reciente de Dupilumab en vida real.

¿En búsqueda del control a Largo plazo plazo en la RSCcPN grave? El Dr. Alejandro Motta describe el estudio DUPIREAL, evidencia reciente de Dupilumab en vida real.

¿En búsqueda del control a Largo plazo plazo en la RSCcPN grave? El Dr. Alejandro Motta describe el estudio DUPIREAL, evidencia reciente de Dupilumab en vida real. 

Zachęcamy do obejrzenia wykładu "Hexyon – nowa nazwa, te same wartości. Szczepienia 6w1 – nowe rekomendacje i możliwości", podczas którego wystąpili eksperci Dr n. med. Ilona Małecka oraz Prof. dr hab. n. med. Profesor Jacek Wysocki.